Barclays
LEGN icon

Barclays’s Legend Biotech LEGN Stock Holding History

Barclays’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.06M Sell
175,322
-4,578
-3% -$123K ﹤0.01% 1838
2026
Q1 		$3.25M Sell
179,900
-93,920
-34% -$1.79M ﹤0.01% 2075
2025
Q4 		$5.95M Buy
273,820
+192,748
+238% +$5.52M ﹤0.01% 2079
2025
Q3 		$2.64M Sell
81,072
-110,659
-58% -$4.09M ﹤0.01% 2672
2025
Q2 		$6.8M Sell
191,731
-42,729
-18% -$1.38M ﹤0.01% 1855
2025
Q1 		$7.96M Buy
234,460
+107,889
+85% +$3.87M ﹤0.01% 1570
2024
Q4 		$4.12M Sell
126,571
-33,779
-21% -$1.4M ﹤0.01% 2331
2024
Q3 		$7.81M Sell
160,350
-35,663
-18% -$1.9M ﹤0.01% 1670
2024
Q2 		$8.68M Sell
196,013
-10,494
-5% -$484K ﹤0.01% 1251
2024
Q1 		$11.6M Buy
206,507
+19,122
+10% +$1.15M ﹤0.01% 1285
2023
Q4 		$11.3M Sell
187,385
-93,709
-33% -$5.94M ﹤0.01% 1434
2023
Q3 		$18.9M Buy
281,094
+197,357
+236% +$13.7M 0.01% 775
2023
Q2 		$5.78M Sell
83,737
-139,801
-63% -$9.13M ﹤0.01% 1267
2023
Q1 		$10.8M Sell
223,538
-248,716
-53% -$12.2M ﹤0.01% 1127
2022
Q4 		$23.6M Buy
472,254
+171,042
+57% +$8.29M 0.01% 812
2022
Q3 		$12.3M Buy
301,212
+8,300
+3% +$390K 0.01% 791
2022
Q2 		$16.1M Buy
292,912
+47,586
+19% +$2.01M 0.01% 811
2022
Q1 		$8.91M Buy
+245,326
New +$9.69M 0.01% 955

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Barclays's LEGN Position: Q2 2026 in Review

Barclays reduced its Legend Biotech (LEGN) stake by 2.5% in Q2 2026, selling an estimated $123K and leaving 175,322 shares worth $5.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1838.

Barclays first reported a position in LEGN in Q1 2022 and has held it in 18 quarters since. The position peaked at $23.6M in Q4 2022. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Barclays held 175,322 shares of Legend Biotech worth $5.06M as of Q2 2026.
  • Barclays sold 4,578 Legend Biotech shares in Q2 2026, an estimated $123K.
  • Legend Biotech made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1838 holding.
  • Barclays first reported a position in Legend Biotech in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Legend Biotech position peaked at $23.6M in Q4 2022.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.